
Chinese biopharmaceutical company founded in 1995 by the United Pharmaceutical Group and located in the Jinqiao biotechnology industrial park within the Shanghai Pilot Free Trade Zone, now backed by Hillhouse Capital and part of the Brilliance group, with registered capital of 61.15 million US dollars. Researches, manufactures and sells genetically engineered vaccines and therapeutic biological products as a national high-tech enterprise. Occupies a twenty thousand square metre site with 24,000 square metres of buildings and runs lines with annual capacity for 12.76 million lyophilised powder injections, 13 million cartridge liquid injections, 10 million capsules and 4 million sachets of granules.
Leave your rating